Compugen (CGEN)vsBeiGene, Ltd. (ONC)
CGEN
Compugen
$2.07
-0.96%
HEALTHCARE · Cap: $198.49M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 7243% more annual revenue ($5.34B vs $72.76M). CGEN leads profitability with a 48.6% profit margin vs 5.4%. CGEN trades at a lower P/E of 5.5x. CGEN earns a higher WallStSmart Score of 71/100 (B).
CGEN
Strong Buy71
out of 100
Grade: B
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.7%
Fair Value
$2.58
Current Price
$2.07
$0.51 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 45 in profit
Keeps 49 of every $100 in revenue as profit
Strong operational efficiency at 83.2%
Revenue surging 44.8% year-over-year
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CGEN
The strongest argument for CGEN centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 48.6% and operating margin at 83.2%. Revenue growth of 44.8% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : CGEN
The primary concerns for CGEN are EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
CGEN profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
CGEN carries more volatility with a beta of 2.96 — expect wider price swings.
CGEN is growing revenue faster at 44.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
CGEN scores higher overall (71/100 vs 42/100), backed by strong 48.6% margins and 44.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Compugen
HEALTHCARE · BIOTECHNOLOGY · USA
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?